FluTrends’ products are designed to help close the “pandemic protection gap” and provide additional prevention during a flu pandemic.

The goals of pandemic prevention are to prevent, mitigate, respond and recover from an influenza pandemic. Current pandemic preparedness plans extend from national to local planning in collaboration with health departments and other agencies across state and local governments. Worldwide, all nations are concerned with the effects associated a pandemic flu outbreak or highly-transmittable seasonal flu outbreak (e.g. H1N1), including the possible disruption at all levels of society and higher mortality rates. In addition, governments are concerned with ensuring their domestic manufacturing infrastructure is adequate to meet surge scenarios. Current programs also include stockpiling vaccines, antivirals, and masks/ventilators to reduce human to human transmission.

In the United States, agencies that have developed pandemic preparedness and response plans include: the Center for Disease Control (CDC); the Department of Health and Human Services (BARDA); Military Medical Heath agencies such as TRICARE; and state health departments. These government agencies typically use a comprehensive portfolio approach to develop and acquire a broad array of medical countermeasures for pandemic flu, including vaccines, therapeutics, diagnostics, and non-pharmaceutical countermeasures.

FluTrends’ products are designed to fulfill the current pandemic protection gap by augmenting current plans. With the stockpiling potential and the Over the Counter availability of the FluTrends’ product, consumers and governments all over the world can be better prepared than with the current vaccines and antiviral programs.

Our products specifically address:

• A 4-6 month delay that might be needed to design and manufacture an effective vaccine
• A time gap between vaccine administration and achieving full potency
• A lack of efficacy from influenza vaccines with the elderly population
• Possible bio-terror virus strains that were designed to have high mutagenicity and capable of defeating current vaccines and antiviral products.
• Augment vaccine protection in the years when there is a mismatch between vaccine seed strain and actual circulating influenza virus

In addition, FluTrends offers services for analyzing pandemic manufacturing requirements, conducting further research to validate the human to human transmission inhibition effectiveness and to reduce the R factor of an uncontrolled epidemic outbreak in a given population.